G. Turchetti, J. Yazdany, I. Palla, E. Yelin, M. Mosca
Istituto di Management, Scuola Superiore Sant`Anna, Pisa, Italy. email@example.com
2012 Vol.30, N°4 ,Suppl.73 - PI 0116, PF 0122
D. Specific diseases
Free to view (click on article PDF icon to read the article)
Systemic lupus erythematosus (SLE) is a chronic, disabling, progressive disease, with many associated comorbidities, affecting patients during prime working years resulting in a high economic burden on society, producing high direct, indirect and intangible costs. In this article, our goals are two-fold. First, we review and discuss studies published in the period 2002–2012 concerning costs of SLE and point out gaps in the published literature. Second, we propose further research studies to advance our understanding of the economic perspective in SLE in the current area of new and emerging therapies. The literature evaluating disease costs in SLE remains limited and to date has only included a small number of countries. Despite these limitations, available studies indicate that SLE has significant socio-economic ramifications. Future studies are needed, especially to assess novel biologic therapies which have been made available or currently under investigation for SLE. An interesting approach in these new economic evaluations in SLE may be represented by the selection of the targets of the treatment to include in the cost-effectiveness and cost-utility analyses. Future treat-to-target strategies will likely include evaluation of their pharmacoeconomic implications.
PMID: 23072767 [PubMed]
Received: 27/09/2012 - Accepted : 28/09/2012 - In Press: 16/10/2012 - Published: 20/11/2012